Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (M...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2014-09, Vol.33 (36), p.4521-4530
Hauptverfasser:	Nguyen, H G, Yang, J C, Kung, H-J, Shi, X-B, Tilki, D, Lara, P N, DeVere White, R W, Gao, A C, Evans, C P
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/2326 631/67/589/466 631/80/82/39 631/80/86 Androgen Receptor Antagonists - therapeutic use Androgens Animals Apoptosis Autophagy Autophagy (Cytology) Autophagy - drug effects Care and treatment Cell Biology Cell Line, Tumor Cellular biology Chemotherapy Chloroquine - pharmacology Clomipramine - pharmacology Drug resistance Gene Expression Regulation, Neoplastic - drug effects Genetic aspects Genetic research Human Genetics Humans Internal Medicine Male Medicine Medicine & Public Health Metformin - pharmacology Mice Mice, SCID Oncology Original original-article Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Signal Transduction - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!